Abstract
In this issue, Gade et al discovered a unique mechanism of hepatocellular carcinoma cells for surviving the ischemia induced by transarterial embolization/transarterial chemoebolization in a state of cell cycle arrest; this function may serve as a defensive shield against conventional chemotherapeutic agents. SummaryIn this issue of Radiology, Gade et al (1) describe a unique mechanism of hepatocellular carcinoma (HCC) cells for surviving ischemia induced by transarterial embolization (TAE)/transarterial chemoembolization (TACE) in a state of cell cycle arrest—a function that may serve as a defensive shield against conventional chemotherapeutic agents. This finding adds to our knowledge and establishes a previously poorly understood mechanism of chemoresistance in HCC. As the Achilles heel in terms of this process, a concurrent upregulation of autophagic flux as an adaptive response to TAE-like ischemia was found by the authors. This is a targetable mechanism that can potentially be exploited for combined therapeutic approaches of embolotherapy and autophagy inhibition in HCC.

This publication has 9 references indexed in Scilit: